COCH predicts survival and adjuvant TACE response in patients with HCC

Chen Wang; Zhi-Wen Ding; Cheng-Gang Zheng; Siyuan Wang; Zhi-Heng Li; Zi-Mu Zhang; Jian Pan; Jian Wang; Chun Yang

doi:10.3892/ol.2021.12536

COCH predicts survival and adjuvant TACE response in patients with HCC

Oncol Lett. 2021 Apr;21(4):275. doi: 10.3892/ol.2021.12536. Epub 2021 Feb 10.

Authors

Chen Wang^{1

2}, Zhi-Wen Ding³, Cheng-Gang Zheng⁴, Siyuan Wang⁵, Zhi-Heng Li¹, Zi-Mu Zhang¹, Jian Pan¹, Jian Wang¹, Chun Yang¹

Affiliations

¹ Institute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, Jiangsu 215025, P.R. China.
² Department of Pediatric Surgery, Hangzhou Children's Hospital, Hangzhou, Zhejiang 310014, P.R. China.
³ Department of Hepatobiliary Surgery, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai 201805, P.R. China.
⁴ Department of Hyperbaric Medicine, Changhai Hospital, Naval Medical University, Shanghai 200433, P.R. China.
⁵ Suzhou Institute of Drug Control, Suzhou, Jiangsu 215031, P.R. China.

Abstract

The aim of the present study was to measure the expression of Cochlin (COCH) and analyze its association with survival, recurrence and the benefits from adjuvant transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) following hepatectomy. Patients with high COCH expression levels had a poorer prognosis in terms of overall and disease-free survival rate compared with those with low COCH expression levels. Further analysis revealed that patients with low COCH expression who received TACE experienced markedly lower early recurrence rates compared with those who did not receive TACE. However, patients with high COCH expression with and without adjuvant TACE after resection experienced no difference in disease recurrence rates. The expression of COCH was found to be associated with hepatitis B virus infection, portal vein tumor thrombosis and Barcelona Clinic Liver Cancer stage in HCC. Therefore, the findings of the present study indicated that clinical detection of COCH expression may help estimate the prognosis of patients with HCC, as well as determine whether to administer TACE after surgery to prevent recurrence.

Keywords: cochlin; hepatocellular carcinoma; recurrence; survival; transarterial chemoembolization.

Grants and funding

This study was supported by grants from the National Natural Science Foundation of China (nos. 81702339, 81802499 and 81802311), Jiangsu Province's Science and Technology Support Program (Social Development) Project (no. BE2017658) and the Applied Foundational Research of Medical and Health Care of Suzhou City (nos. SYSD2018206, SYS2019079 and SYS2018104).